▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3041 by analyst upside · 2026-06-27
QTTB
Q32 Bio Inc.
Healthcare · Market Cap $223M · P/E 4.7x
ANALYST PRICE TARGET
+8.2%
implied upside to consensus target
Current Price $13.17
Consensus Target $14.25
Bull Target $20.0
Bear Target $10.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
1
Sell
0
52-Week Low $1.34
52-Week High $14.85
YTD Return +282.8%
FUNDAMENTALS
Market Cap $223M
P/E Ratio (TTM) 4.7x
Forward P/E -2.5x
EPS (TTM) $2.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $54M
Profit Margin 61.9%
52-WEEK RANGE
52-Week Low $1.34
52-Week High $14.85
Current Price $13.17
Bear Target $10.0
Bull Target $20.0
● Now $13.17 ● Target $14.25
TRADING DATA
Avg Volume 755K
YTD Return +282.8%
Analyst Count 4
Consensus Buy
Upside to Target +8.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Q32 Bio Inc. (QTTB) is currently trading at $13.17 with a Wall Street consensus price target of $14.25, implying potential upside of 8.2% over the next 12 months. 4 analysts currently cover QTTB, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $10.0.

QTTB operates in the Healthcare sector with a market capitalisation of $223M. The stock is up 282.8% year-to-date and is currently trading near the upper end of its 52-week range of $1.34 – $14.85.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

EMBC +14.6%
Embecta Corp.
$207M · P/E 1.8x · Underperform
PDEX +13.9%
Pro-Dex, Inc.
$196M · P/E 18.2x · Buy
SPOK +31.5%
Spok Holdings, Inc.
$222M · P/E 18.1x · Hold
ORMP +33.8%
Oramed Pharmaceuticals Inc.
$191M · P/E 1.8x · Hold
INFU +48.0%
InfuSystem Holdings, Inc.
$203M · P/E 27.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for QTTB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho ● Initiated
Outperform 2026-05-22 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-05-18 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-05 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-02-25 31% win rate (48 calls)
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-03-12 Building track record
BMO Capital ↓ Downgrade
Outperform → Market Perform 2025-02-11 Building track record
Piper Sandler ↓ Downgrade
Overweight → Neutral 2025-02-11 14% win rate (7 calls)
BMO Capital — Reiterated
Outperform → Outperform 2024-12-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
12/30
Consensus clarity
15/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →